Lexeo Therapeutics was established as a genetic medicine biotechnology company focused on pioneering advanced cardiovascular and CNS gene therapies. The organization was built by combining pioneering academic research with dedicated venture capital backing to advance clinical-stage pipeline candidates. Over subsequent years, it scaled its operational infrastructure, secured significant private financing rounds, and completed a public stock offering to fund its ongoing clinical trials and genetic delivery technology advancements.